NEUROCRINE BIOSCIENCES INC Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
NEUROCRINE BIOSCIENCES INC (NBIX) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $659.10 million as of 2021-12-31, per its 10-K filed 2022-02-11.
Discontinued › Notes › Investments › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2022-02-11
- 2021-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $659.10M.
- 2021-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $405.80M.
- 2021-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $245.50M.
- 2020-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $95.00M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months as first filed |
|---|---|---|
| 2021-12-31 | $659.10M 10-K · filed 2022-02-11 | |
| 2021-09-30 | $405.80M 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $245.50M 10-Q · filed 2021-08-03 | |
| 2020-12-31 | $95.00M 10-K · filed 2022-02-11 | |
| 2020-03-31 | $429.70M 10-Q · filed 2020-05-06 | |
| 2019-09-30 | $142.54M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $53.57M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $94.78M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $234.12M 10-K · filed 2020-02-07 | $331.62M 10-K · filed 2019-02-08 |
| 2017-12-31 | $331.62M 10-K · filed 2020-02-07 | $460.25M 10-K · filed 2019-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |